|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||4.1900 - 4.2850|
|52 Week Range||3.1040 - 5.3800|
|Beta (3Y Monthly)||0.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.05|
Securities subscribed by American and European qualified investors. AB Science S.A. (the « Company » or « AB Science »), NYSE Euronext – FR0010557264 - AB), announces today a private placement of new shares with subscription warrants attached (the “Securities”) that result in gross proceeds for the Company of approximately EUR 10.0 million by accelerated book-building procedure completed on August 16, 2019 after the market closed.
FR0010557264 - AB), announces today that AB science will present a corporate overview at two upcoming healthcare conferences, the 26th Annual NewsMakers in the Biotech Industry taking place on September 6, 2019 in New York, and the H.C. Wainwright 21st Annual Healthcare Conference taking place on September 9-10, 2019 in New York. “We are pleased to be invited to present AB Science at these two important healthcare conferences” stated Alain Moussy, Co-founder and CEO of AB Science.
FR0010557264 - AB) provides an update on its masitinib clinical program. As part of its restructuring performed over the last 2 years, AB Science has decided to streamline its clinical masitinib portfolio in order to increase shareholder value creation.
FR0010557264 - AB), today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta-membrane (JM) domain of c-Kit. The phase 3 trial (AB08026) was an open-label, controlled study comparing masitinib to dacarbazine and designed to assess the safety and efficacy of masitinib 7.5 mg/kg/day in patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta-membrane (JM) domain of c-Kit.
Paris, July 09, 2019, 8am Summary of the July 8 2019 web conference Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure.
FR0010557264 - AB) announces today that the European Medicine Agency (EMA) has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure. AB Science will host a live webcast on AB8939, focusing on the Scientific Advice procedure with EMA and resulting validated clinical development program of AB8939 in acute myeloid leukemia (AML).
FR0010557264 - AB) reports the outcome from the interim analysis of study AB09004 in Alzheimer’s disease. Study AB09004 is an international, randomized, placebo-controlled, phase 3 study evaluating masitinib as a treatment of patients with confirmed mild to moderate Alzheimer’s disease. This study compares the efficacy and safety of masitinib when administered as an add-on therapy to cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, to placebo as add-on to cholinesterase inhibitor and/or memantine.
IDMC recommends to continue study. AB Science SA (NYSE Euronext - FR0010557264 - AB) announces the positive recommendation of the Independent Data Monitoring Committee (IDMC), following the interim analysis of study AB12005 in the first-line treatment of pancreatic cancer.
FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is providing a summary of the web conference held on June 5, 2019 on its clinical programs outside of amyotrophic lateral sclerosis and mastocytosis. The development of masitinib in asthma is based on the targeting of mast cells [1 ;2 ;3;4]. The clinical development program in asthma is comprised of one proof of concept study , one pivotal study is severe asthma uncontrolled by oral corticosteroids (OCS), and one pivotal study in severe asthma uncontrolled by inhaled corticosteroids (ICS).
FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is providing a summary of the web conference held on 4 June 2019 on its clinical programs in amyotrophic lateral sclerosis and mastocytosis. ANSM lifted on 27 May 2019 its decision to suspend clinical trials. AB Science is now back to a normal process to get authorization for new clinical trials.
FR0010557264 - AB) is hosting a web conference to communicate its outlook for 2019. The web conference will be held in two parts, on Tuesday June 4 and on Wednesday June 5, from 5.30 pm to 7 pm CET.
FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces today that the Agence Nationale de la Sécurité des Médicaments (ANSM - French National Agency for Medicines and Health Products Safety) has lifted its suspension of clinical studies conducted by AB Science in France. As a reminder, the ANSM decision to suspend clinical studies was made on May 11, 2017.
Paris, April 30, 2019 – 6pm Net loss of 26.1M€ for the year 2018 Cash position of 11.6M€ as of 31 December 2018, plus 5.7M€of 2018 tax credit.
Paris, 16 April 2019, 8pm New preclinical data for masitinib in amyotrophic lateral sclerosis (ALS) presented at the 2019 Muscular Dystrophy Association Conference.
Paris, March 21, 2019, 6.30pm AB Science Announces Acceptance of Abstract for Oral Presentation at the 2019 Muscular Dystrophy Association Conference Data Provides Further Evidence on Masitinib`s Mode ...
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see fellow investors suffer a loss. Imagine ifRead More...
In 2001 Alain Moussy was appointed CEO of AB Science S.A. (EPA:AB). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a Read More...
FR0010557264 - AB), a pharmaceutical company specialized in the research and development of protein kinase inhibitors (PKIs), has completed reorganization of its clinical development activity to ensure compliance with good clinical practices as a consequence of the ANSM decision to put AB Science studies on clinical hold in France. AB Science provides here the main achievements of this restructuring.
FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces today that the masitinib phase 3 study in Alzheimer`s disease has completed patient recruitment.